CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on

Positive
AI Analysis

Summary

Repligen announced the acquisition of BioLife for $1.5B to expand its exposure to cell therapy, a product platform used by top-selling therapies from BMS, J&J, and Gilead.

Importance:7/10
Sentiment:
0.60
M&Acell therapyacquisitionBioLifeRepligen
Related Companies

Read the original article

Published by BioSpace on July 22, 2026 2:12 PM

Read Original